Koyfin Home > Directory > Health Care > Adverum Biotechnlgs > Capital Expenditures

Adverum Biotechnlgs Capital Expenditures Chart (ADVM)

Adverum Biotechnlgs annual/quarterly Capital Expenditures from 2013 to 2020.
  • Adverum Biotechnlgs Capital Expenditures for the quarter ending June 06, 2020 was $-3m a -98.56% increase of 3m year over year
  • Adverum Biotechnlgs Capital Expenditures for the last 12 months ending June 06, 2020 was $-22m a 49.61% decrease of -11m year over year
  • Adverum Biotechnlgs Annual Capital Expenditures for 2019 was $-19m a 95.80% decrease of -18m from 2018
  • Adverum Biotechnlgs Annual Capital Expenditures for 2018 was $-1m a -25.59% increase of 0m from 2017
  • Adverum Biotechnlgs Annual Capital Expenditures for 2017 was $-1m a -137.40% increase of 1m from 2016
Other Cash Flow Metrics:
  • Adverum Biotechnlgs Cash Flow from Operations for the quarter ending December 12, 2018 was $-13m a -2.00% increase of 0m year over year
  • Adverum Biotechnlgs Levered Free Cash Flow (FCF) for the quarter ending December 12, 2018 was $-26m a 70.14% decrease of -18m year over year
  • Adverum Biotechnlgs Total Revenue for the quarter ending September 09, 2018 was $1m a 44.66% increase of 0m year over year
View Chart On Koyfin

Quarterly ADVM Capital Expenditures Data

06/2020$-3m
03/2020$-4m
12/2019$-8m
09/2019$-6m
06/2019$-2m
03/2019$-2m
12/2018$0m
09/2018$0m
06/2018$0m
03/2018$0m

Annual ADVM Capital Expenditures Data

2019$-19m
2018$-1m
2017$-1m
2016$-2m
2015$-3m
2014$-1m
2013$0m
2012$0m